PNTG

The Pennant Group, Inc.

Fundamental data last updated:November 20, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Care Facilities

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

02/24/2027

Business Summary

The Pennant Group, Inc. is a U.S.-based healthcare provider, delivering a diverse range of services through two core divisions: Home Health and Hospice Services, and Senior Living Services. The company's Home Health segment offers in-home clinical support, encompassing nursing, speech, occupational, and physical therapy, as well as medical social work and home health aide assistance. Its Hospice services focus on providing comprehensive clinical care, education, and counseling to meet the physical, spiritual, and psychosocial needs of terminally ill patients and their families. In its Senior Living division, Pennant provides residential accommodations, organized activities, meals, housekeeping, and aid with daily living tasks for seniors who are either independent or require some support. As of December 31, 2021, the company's extensive operational footprint included 88 home health and hospice agencies and 54 senior living communities, collectively featuring 4,127 senior living units. These facilities are located across Arizona, California, Colorado, Idaho, Iowa, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. The Pennant Group, Inc. was established in 2019 and maintains its corporate headquarters in Eagle, Idaho.

 


VALUATION

P/E

34.68

Market Cap ($M USD)

$1.27B

Forward P/E

25.87

PEG

1.63

PRICE TO SALES

1.08

PRICE TO BOOK

3.36

EV / EBITDA

23.28

5-Year Average P/E

Free Cash Flow Yield

2.02%

DCF Value

$-9.22

Graham Number

$15.74

Price to FCF

49.39

EV to FCF

67.43

Earnings Yield

2.84%

FCF Yield

2.02%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$1.02

Next Year EPS Growth Estimate

$1.39

Next Year Revenue Growth Estimate

$1.18B

Return on Equity (ROE)

10.15%

FREE CASH FLOW

Operating Margin

5.94%

Debt-to-Equity

1.28

Piotroski F-Score

6

Altman Z-Score

2.73

Return on Invested Capital (ROIC)

5.62%

Current Ratio

1.18

Quick Ratio

1.18

Net Debt to EBITDA

6.23

Interest Coverage

9.76

Gross Profit margin

13.37%

FCF PER SHARE

$0.73

REVENUE PER SHARE

$33.57

Gainseekers Quantitative Analysis

Summary

The market seems to be mispricing The Pennant Group, Inc., as its snapshot price traded significantly above its DCF value, suggesting overvaluation. With a Forward P/E of 18.70, the company is priced for growth, yet the earnings yield of 2.43% indicates a modest return on investment. The Altman Z-score of 2.76 suggests moderate financial health, not quite in distress but not a fortress either. Despite these concerns, the Graham Number of 13.99 implies a conservative intrinsic value, hinting at potential downside risk. Overall, the valuation appears stretched, demanding flawless execution to justify its current levels.

AI Exposure / Tech Reliance

Operating within the healthcare sector, The Pennant Group is well-positioned to leverage AI for operational efficiencies, particularly in patient care and administrative processes. As medical facilities increasingly adopt tech-driven solutions, the company could enhance service delivery and reduce costs. However, the pace of tech adoption in healthcare remains a critical factor for sustained competitive advantage.

The Bull Case

For the discerning GARP investor, The Pennant Group offers a compelling narrative of capital efficiency and growth potential. With a robust ROIC of 6.99% and a Piotroski F-Score of 5, the company demonstrates solid operational health. Its FCF Yield, though modest, indicates some level of cash generation capability. The operating margin of 5.66% suggests effective cost management, hinting at potential pricing power in its niche market. These metrics collectively paint a picture of a company with the potential to deliver long-term value.

The Bear Case

Despite some strengths, the stock is not without its pitfalls. The Price/Book ratio of 3.60 and Price/Sales of 1.22 suggest a premium valuation, potentially overextended given its proximity to the 52-week high. The EV to EBITDA ratio of 25.20 further underscores the high expectations baked into its current price. Additionally, the net debt to EBITDA of 6.59 raises concerns about leverage and financial flexibility. These factors, combined with a zero dividend yield, present significant risks for investors seeking immediate returns.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$47.33

Institutional Ownership %

1-Year Beta

1.30

Insider Buying % (6 Mo)

Distance to 52-Week High

22.65%

Distance to 52-Week Low

32.19%

EARNINGS SURPRISE %

-2.07%

50-DAY SMA

$40.08

200-DAY SMA

$35.85

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.